Long term survival achieved through combination of almonertinib and pyrotinib in egfr-mutant/her2-amplified advanced nsclc patient: a case report and literature review

HIGHLIGHTS

• What: In the study, patients who failed treatment with EGFR-TKI responded to pyrotinib with an objective response rate (ORR) of 30.8% and mPFS of 7.2 months.
• Who: HER et al. from the Sichuan University, China have published the article: Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-ampli ed advanced NSCLC patient: a case report and literature review, in the Journal: (JOURNAL) of 28/05/2019
• How: This article presents the treatment process of an EGFR-mutant/ HER2-amplified NSCLC patient and summarizes the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.